A director at Umicore S.A. bought 14,000 shares at 7.700EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Trumps reciprocal tariffs caused a massive blow to equity markets, following a pressured period of escalating trade wars. Retaliatory measures can further heavily damage market confidence, as seen Friday when China announced their 34% tarrif of US goods. International trade policies have never moved this erratic and untransparant, with uncertainty and volatility being the baseline for now. In this report we highlight the key stocks in our coverage relevant to this discussion.
Last week's long awaited strategy update highlighted Umicore's ambition to try to monetize past investments in Battery Materials, acknowledging that some additional capex and equity investment into the Ionway JV are still necessary to achieve this. In the meantime, the company will actively explore partnerships in Battery Materials. The financial targets for Battery Materials were above our expectations and the same can be said for the foundation businesses, particularly Catalysis, which is to b...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: FERROVIAL, IBERDROLA, REPSOL. EUROPA: ENI, ING GROEP, UNICREDIT. Semana negativa para los mercados Caídas cercanas al -1,0% en Europa en el cierre de una semana marcada nuevamente por la imposición de aranceles. Junto al FTSE 100, el Ibex fue el índice europeo que mejor resistió las caídas y logró retener los 13.300 puntos. Así, en el STOXX 600, la mayoría de los sectores (14/20) cerraron la semana con pérdidas, lideradas por Tecnología y Autos fre...
Below are some key highlights from yesterday's CMD. We remind that Umicore announced a € 1-1.2bn adjusted EBITDA target for 2028 with the upside vs our € 0.8bn forecast coming from both Battery Materials as well Catalysis, which is guided to further grow share in the LDV market. We will up our forecasts somewhat following the CMD. Even after yesterday's share rebound, valuation seems attractive and we maintain our Accumulate rating and € 12 target price.
This note gathers feedback from the group meetings and the panels. In total 21 companies were presented in group meetings and/or panels. More than 100 guests found their way to the venue either physical or virtual (only panels). The 2 panels made for informative additions to the C-level meetings and a nice platform for discussion. Wednesday afternoon concentrated 4 experts from Logistic companies (CTP, Montea, VGP, WDP) for an interesting discussion on brownfields: " an answer to the scarcity of...
Arcadis: Large contract in Resilience. ASM International: Highlights from CFO roadshow. Exor: Exor buying back Exor shares. Fastned: 2H24 results, cost pressure. Flow Traders: February volumes elevated in EMEA. Montea: JV with Weerts in Belgium. Sligro: FY24 results in line, weak 1Q25 outlook. Sofina: Final NAV a tad higher. Umicore: CMD targets – no big bang
At the occasion of the long awaited CMD & Strategy Update, Umicore revealed ambitious targets for 2028. EBITDA28 target stands at €1-1.2bn well above our € 0.8bn estimate. While all divisional targets exceed our estimates the targets for Catalysis stand out most. We remind that Catalysis and to a lesser extent Recycling are facing structural headwinds from the ongoing electrification, whilst still generating top notch cash flow. Taking into account the current distressed valuation, we maintain ...
Arcadis: Further in German rail. CVC Capital Partners: They beat, they score. D'Ieteren: US Belron peer Boyd 4Q24 a bit ahead, weak 2025 early outlook. Fastned: Preview FY24. IBA: 2H24 better REBIT, net cash but outlook on the low side. Proximus: Interim leadership announced. UCB: Peer Immunovant reports mixed results in gMG Zabka: Peer Jeronimo Martins FY24 results
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.